Amerikanische Gesellschaft für Hirudotherapie

Plantar Warts (Verruca Plantaris, Refractory)

Highly investigational use for refractory plantar warts (HPV-mediated) after cryotherapy and salicylic acid failure; very limited anecdotal evidence.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for plantar warts (verruca plantaris). FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
Welche Evidenz existiert?
Tier C (investigational). Anecdotal only. Evidence-based first-line management of plantar warts is salicylic acid keratolytic therapy and cryotherapy (each with ~50-70% cure rates over 12-16 weeks). Refractory warts may respond to topical 5-fluorouracil, intralesional bleomycin, cantharidin, candida antigen injection, or laser ablation. Many plantar warts also resolve spontaneously over 12-24 months.
Hauptrisiken
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Spread of HPV to surrounding skin from disturbing the wart surface
  • Painful prolonged bleeding from a thick keratinized plantar surface that does not seal easily
Wer dies nicht in Betracht ziehen sollte
  • Patients with diabetes, peripheral arterial disease, or peripheral neuropathy (high foot-ulcer risk)
  • Patients whose warts have not had a proper trial of salicylic acid, cryotherapy, or other standard therapy
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with severe anemia (hemoglobin under 10 g/dL)
  • People with an active infection at the planned application site
  • Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
Was Sie Ihren Kliniker fragen sollten
  • Have I tried salicylic acid for at least 12 weeks?
  • Have I tried cryotherapy for 2-3 sessions?
  • Have intralesional options like bleomycin or candida antigen been considered?
  • What is the published cure rate for leeches versus a 70 percent cure rate for standard therapy?
  • What is the bleeding-control plan on the bottom of the foot, where dressings shift with walking?
  • How will viral spread to other foot skin be prevented?
Wann dringende medizinische Versorgung suchen
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Inability to bear weight on the foot due to pain or new wound
  • Spreading streaks of redness up the foot or leg

Was dies NICHT bedeutet

  • It does not mean leech therapy is FDA-cleared for plantar warts — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace standard therapy: salicylic acid, cryotherapy, and (for refractory cases) intralesional injections or laser.
  • It does not eliminate the underlying HPV infection that caused the wart.
  • It does not prevent recurrence at the same or new sites.
  • It does not have controlled-trial evidence for this indication.

Clinical Profile

Category
dermatological
ICD-10
B07.0, B07.9
Safety tier
low

Evidence Summary

Plantar warts are HPV-mediated benign epithelial proliferations conventionally treated with topical salicylic acid (~60% efficacy) and cryotherapy (~50% efficacy), with second-line options including intralesional bleomycin or candida antigen, pulsed dye laser, or surgical paring with cantharidin. Direct evidence for leech therapy is limited to a single case report describing clearance of a longstanding giant plantar wart after medicinal leech application in an immunosuppressed patient; this is grade D anecdotal evidence, not a case series, and the mechanism is unclear (possible local immune stimulation). Most plantar warts resolve spontaneously over 1-2 years.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Singh K et al. (2020), n=12

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Mosaic warts covering >5 cm area (immune-targeted therapy preferred)
  • Diabetic foot or peripheral neuropathy
  • Immunocompromise predisposing to HPV proliferation
  • Suspected verrucous carcinoma (biopsy required)

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Plantar Warts (Verruca Plantaris, Refractory) — Hirudotherapy Evidence | ASH